Reported results
- Total revenue was $0.2 million for the third quarter of 2026.
- Operating expenses were $16.9 million for the third quarter of 2026.
- Net loss was $15.6 million for the third quarter of 2026.
- Cash, cash equivalents, and investments were $114.3 million as of September 30, 2026.
- Net loss per share attributable to common stockholders, basic and diluted was $(0.12) for the third quarter of 2026.
Guidance
- Nautilus expects to receive up to $6 million to deploy its Voyager Platform to measure proteoforms driving Alzheimer’s disease and cancer.
- Planned instrument availability in the middle of 2027.
- Advanced the proteoform pipeline needed to deliver twenty assays planned through mid-2028.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-26 (8-K, Item 2.02). Read the original filing on sec.gov.
